Galantamine
- Generic Name
- Galantamine
- Brand Names
- Razadyne
- Drug Type
- Small Molecule
- Chemical Formula
- C17H21NO3
- CAS Number
- 357-70-0
- Unique Ingredient Identifier
- 0D3Q044KCA
- Background
Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as Galanthus nivalis. Galantam...
- Indication
Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type.
- Associated Conditions
- Mild to Moderate Dementia Due to Alzheimer's Disease, Mild Dementia of the Alzheimer's Type, Moderate Alzheimer's Type Dementia
- Associated Therapies
- -
Alzheimer's Disease Therapeutics Market With 18.8% CAGR
The Alzheimer’s disease therapeutics market is projected to grow from USD 5.5 billion in 2023 to USD 30.8 billion by 2033, at a CAGR of 18.8%, driven by an aging global population and advancements in treatment. North America leads with a 42.5% share in 2023. Key factors include increased awareness, a robust drug pipeline, and rising prevalence of Alzheimer’s disease worldwide.
STUDY: Cholinesterase Inhibitors Show Promise for Lewy Body Dementia
A 10-year study by Karolinska Institutet found that cholinesterase inhibitors (ChEIs) like donepezil and galantamine showed promise in reducing cognitive decline in LBD, with rivastigmine reducing mortality risk. Higher ChEI doses provided greater cognitive benefits, but memantine showed no significant cognitive effect. The study highlights the need for long-term follow-ups and the lack of universal benchmarks for cognitive decline reduction.
FDA-Approved Zunveyl for Alzheimer's Symptoms On the Way in 2025
FDA approved Zunveyl, a new oral Alzheimer’s treatment with fewer side effects, based on galantamine, to be available by 2025. Zunveyl aims to improve quality of life by reducing gastrointestinal side effects common in other cholinesterase inhibitors.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath